Akahane K, Sekiguchi M, Une T, Osada Y
Research Institute, Daiichi Pharmaceutical Co., Ltd., Tokyo, Japan.
Antimicrob Agents Chemother. 1989 Oct;33(10):1704-8. doi: 10.1128/AAC.33.10.1704.
The relationship between the chemical structure and epileptogenic activity of quinolones was investigated. When the quinolones were administered intravenously to mice concomitantly with oral biphenylacetic acid, a major metabolite of the nonsteroidal antiinflammatory drug fenbufen, enoxacin, norfloxacin, ciprofloxacin, and pipemidic acid, which have an unsubstituted piperazine moiety at the 7 position of their parent nuclei, provoked clonic convulsions and subsequent death at doses of 6.25 mg/kg or more in a dose-dependent manner. AM-1091 and T-3262, which have an unsubstituted aminopyrrolidine moiety at their 7 positions, were less epileptogenic than the compounds listed above were. In contrast, ofloxacin, AT-4140, and nalidixic acid, which have piperazine substituted with methyl group(s) or no piperazine moiety at their 7 positions, never induced convulsions, even at doses of 100 mg/kg. Lomefloxacin, which has a 3-methyl piperazine, however, provoked convulsions at doses of 6.25 mg/kg or more. In the presence of biphenylacetic acid, all the test quinolones except nalidixic acid competitively inhibited [3H]muscimol binding to receptor sites for gamma-aminobutyric acid (GABA) in vitro. Nalidixic acid did not inhibit the binding at all, even at the highest concentration tested, i.e., 10(-4) M. The 50% inhibition doses for [3H]muscimol binding varied within 4 orders of magnitude or more, between 10(-8) to more than 10(-4) M for various compounds, and there was a close correlation between the epileptogenic activities of quinolones and their inhibitory potencies for [3H]muscimol binding to GABA receptor sites. These results indicate that the epileptogenic activity of quinolones possibly relates to the GABA-like structures of substituents at their 7 positions, which act as antagonists of GABA receptors.
研究了喹诺酮类药物的化学结构与致痫活性之间的关系。当将喹诺酮类药物与非甾体抗炎药芬布芬的主要代谢产物联苯乙酸同时静脉注射给小鼠时,在其母核7位具有未取代哌嗪部分的依诺沙星、诺氟沙星、环丙沙星和吡哌酸,以剂量依赖性方式在6.25mg/kg或更高剂量时引发阵挛性惊厥并随后死亡。在其7位具有未取代氨基吡咯烷部分的AM-1091和T-3262,其致痫性低于上述化合物。相反,在其7位具有被甲基取代的哌嗪或没有哌嗪部分的氧氟沙星、AT-4140和萘啶酸,即使在100mg/kg剂量下也从未诱发惊厥。然而,具有3-甲基哌嗪的洛美沙星在6.25mg/kg或更高剂量时引发惊厥。在联苯乙酸存在下,除萘啶酸外的所有测试喹诺酮类药物在体外均竞争性抑制[3H]蝇蕈醇与γ-氨基丁酸(GABA)受体位点的结合。萘啶酸即使在测试的最高浓度即10^(-4)M时也完全不抑制结合。[3H]蝇蕈醇结合的50%抑制剂量在不同化合物之间在4个数量级或更多范围内变化,介于10^(-8)至超过10^(-4)M之间,并且喹诺酮类药物的致痫活性与其对[3H]蝇蕈醇结合GABA受体位点的抑制效力之间存在密切相关性。这些结果表明,喹诺酮类药物的致痫活性可能与其7位取代基的GABA样结构有关,这些结构作为GABA受体的拮抗剂起作用。